TSC2 and neoplasm: Recent studies demonstrate that lung-targeted lipid nanoparticles delivering functional TSC2 mRNA can restore tumor suppressor activity, inhibit mTORC1 signaling, and reduce cystic lung damage in preclinical models, offering a potential disease-modifying approach.